11/11
11:42 am
igms
IGM Biosciences, Inc. (NASDAQ: IGMS) had its price target raised by analysts at Stifel Nicolaus from $25.00 to $27.00. They now have a "buy" rating on the stock.
Low
Report
IGM Biosciences, Inc. (NASDAQ: IGMS) had its price target raised by analysts at Stifel Nicolaus from $25.00 to $27.00. They now have a "buy" rating on the stock.
11/8
07:32 am
igms
IGM Biosciences GAAP EPS of -$1.01 misses by $0.19, revenue of $0.52M beats by $0.28M [Seeking Alpha]
Medium
Report
IGM Biosciences GAAP EPS of -$1.01 misses by $0.19, revenue of $0.52M beats by $0.28M [Seeking Alpha]
11/8
07:00 am
igms
IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Medium
Report
IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update
11/7
06:58 am
igms
IGM Biosciences (NASDAQ:IGMS) Is In A Good Position To Deliver On Growth Plans [Yahoo! Finance]
Low
Report
IGM Biosciences (NASDAQ:IGMS) Is In A Good Position To Deliver On Growth Plans [Yahoo! Finance]
11/7
02:19 am
igms
Medivir AB (OSTO:MVIR) Q3 2024 Earnings Call Highlights: Strategic Collaborations and Financial ... [Yahoo! Finance]
Low
Report
Medivir AB (OSTO:MVIR) Q3 2024 Earnings Call Highlights: Strategic Collaborations and Financial ... [Yahoo! Finance]
11/4
07:00 am
igms
IGM Biosciences to Present at Three Upcoming Investor Conferences
Medium
Report
IGM Biosciences to Present at Three Upcoming Investor Conferences
10/18
08:32 am
igms
IGM Biosciences, Inc. (NASDAQ: IGMS) had its price target raised by analysts at Royal Bank of Canada from $17.00 to $20.00. They now have an "outperform" rating on the stock.
Low
Report
IGM Biosciences, Inc. (NASDAQ: IGMS) had its price target raised by analysts at Royal Bank of Canada from $17.00 to $20.00. They now have an "outperform" rating on the stock.
10/2
08:23 am
igms
The START Center for Cancer Research Appoints Dr. Chris Takimoto as Chief Medical Officer [Yahoo! Finance]
Medium
Report
The START Center for Cancer Research Appoints Dr. Chris Takimoto as Chief Medical Officer [Yahoo! Finance]
10/1
01:17 pm
igms
IGM Biosciences, Inc. (NASDAQ: IGMS) had its price target lowered by analysts at Guggenheim from $25.00 to $20.00. They now have a "buy" rating on the stock.
Low
Report
IGM Biosciences, Inc. (NASDAQ: IGMS) had its price target lowered by analysts at Guggenheim from $25.00 to $20.00. They now have a "buy" rating on the stock.
10/1
11:17 am
igms
IGM Biosciences, Inc. (NASDAQ: IGMS) had its price target lowered by analysts at Wedbush from $25.00 to $22.00. They now have an "outperform" rating on the stock.
Low
Report
IGM Biosciences, Inc. (NASDAQ: IGMS) had its price target lowered by analysts at Wedbush from $25.00 to $22.00. They now have an "outperform" rating on the stock.
10/1
11:17 am
igms
IGM Biosciences, Inc. (NASDAQ: IGMS) had its price target lowered by analysts at Royal Bank of Canada from $20.00 to $17.00. They now have an "outperform" rating on the stock.
Low
Report
IGM Biosciences, Inc. (NASDAQ: IGMS) had its price target lowered by analysts at Royal Bank of Canada from $20.00 to $17.00. They now have an "outperform" rating on the stock.
10/1
07:57 am
igms
IGM Biosciences, Inc. (NASDAQ: IGMS) was downgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "underweight" rating. They now have a $9.00 price target on the stock, down previously from $12.00.
High
Report
IGM Biosciences, Inc. (NASDAQ: IGMS) was downgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "underweight" rating. They now have a $9.00 price target on the stock, down previously from $12.00.
10/1
07:36 am
igms
IGM Biosciences, Inc. (NASDAQ: IGMS) was downgraded by analysts at Truist Financial Co. from a "buy" rating to a "hold" rating. They now have a $12.00 price target on the stock, down previously from $24.00.
High
Report
IGM Biosciences, Inc. (NASDAQ: IGMS) was downgraded by analysts at Truist Financial Co. from a "buy" rating to a "hold" rating. They now have a $12.00 price target on the stock, down previously from $24.00.
9/30
04:12 pm
igms
IGM Biosciences Announces Strategic Pivot to Focus Exclusively on Autoimmunity [Yahoo! Finance]
Medium
Report
IGM Biosciences Announces Strategic Pivot to Focus Exclusively on Autoimmunity [Yahoo! Finance]
9/30
04:01 pm
igms
IGM Biosciences Announces Strategic Pivot to Focus Exclusively on Autoimmunity
High
Report
IGM Biosciences Announces Strategic Pivot to Focus Exclusively on Autoimmunity
9/27
07:33 am
igms
While shareholders of IGM Biosciences (NASDAQ:IGMS) are in the black over 1 year, those who bought a week ago aren't so fortunate [Yahoo! Finance]
Low
Report
While shareholders of IGM Biosciences (NASDAQ:IGMS) are in the black over 1 year, those who bought a week ago aren't so fortunate [Yahoo! Finance]
9/18
11:41 am
igms
IGM Biosciences (IGMS) Surges 11.6%: Is This an Indication of Further Gains? [Yahoo! Finance]
Medium
Report
IGM Biosciences (IGMS) Surges 11.6%: Is This an Indication of Further Gains? [Yahoo! Finance]
9/10
04:05 pm
igms
IGM Biosciences to Present at the Stifel 2024 Virtual Immunology and Inflammation Summit
Medium
Report
IGM Biosciences to Present at the Stifel 2024 Virtual Immunology and Inflammation Summit
9/5
08:06 am
igms
IGM Biosciences, Inc. (NASDAQ: IGMS) had its price target lowered by analysts at HC Wainwright from $12.00 to $11.00. They now have a "neutral" rating on the stock.
Medium
Report
IGM Biosciences, Inc. (NASDAQ: IGMS) had its price target lowered by analysts at HC Wainwright from $12.00 to $11.00. They now have a "neutral" rating on the stock.
8/23
12:17 pm
igms
IGM Biosciences, Inc. (NASDAQ: IGMS) had its price target lowered by analysts at Truist Financial Co. from $25.00 to $24.00. They now have a "buy" rating on the stock.
Medium
Report
IGM Biosciences, Inc. (NASDAQ: IGMS) had its price target lowered by analysts at Truist Financial Co. from $25.00 to $24.00. They now have a "buy" rating on the stock.